相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma
Tadashi Shiraishi et al.
ONCOLOGY (2021)
Immunosuppression Factors PD-1, PD-L1, and IDO1 and Colorectal Cancer
O. Kovaleva et al.
DOKLADY BIOCHEMISTRY AND BIOPHYSICS (2021)
Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy
Rong Fu et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
Angelo Castello et al.
CANCERS (2020)
Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy
Shoujian Ji et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
Jacob J. Orme et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients WithEGFRMutations
Yijun Jia et al.
FRONTIERS IN ONCOLOGY (2020)
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
P. Hofman et al.
ANNALS OF ONCOLOGY (2019)
SOLUBLE SPD-L1 AND SERUM AMYLOID A1 AS POTENTIAL BIOMARKERS FOR LUNG CANCER
Dragana Jovanovic et al.
JOURNAL OF MEDICAL BIOCHEMISTRY (2019)
Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlations
N. E. Kushlinskii et al.
ONKOUROLOGIYA (2019)
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
Adrien Costantini et al.
ONCOIMMUNOLOGY (2018)
Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Hazem I. Assi et al.
CANCER (2018)
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Yusuke Okuma et al.
LUNG CANCER (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib
Steffen Filskov Sorensen et al.
LUNG CANCER (2016)
Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
Yongjing Chen et al.
CYTOKINE (2011)
分享论文
